Research ExplorerPublicationsTrophoblast Cell Surface Antigen 2 Expression in Human Tumor...

Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors

Standard

Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. / Dum, David; Taherpour, Noushin; Menz, Anne; Höflmayer, Doris; Völkel, Cosima; Hinsch, Andrea; Gorbokon, Natalia; Lennartz, Maximilian; Hube-Magg, Claudia; Fraune, Christoph; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Marx, Andreas H; Simon, Ronald; Burandt, Eike; Krech, Till; Luebke, Andreas M.

In: PATHOBIOLOGY, Vol. 89, No. 4, 2022, p. 245-258.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dum, D, Taherpour, N, Menz, A, Höflmayer, D, Völkel, C, Hinsch, A, Gorbokon, N, Lennartz, M, Hube-Magg, C, Fraune, C, Bernreuther, C, Lebok, P, Clauditz, TS, Jacobsen, F, Sauter, G, Uhlig, R, Wilczak, W, Steurer, S, Minner, S, Marx, AH, Simon, R, Burandt, E, Krech, T & Luebke, AM 2022, 'Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors', PATHOBIOLOGY, vol. 89, no. 4, pp. 245-258. https://doi.org/10.1159/000522206

APA

Dum, D., Taherpour, N., Menz, A., Höflmayer, D., Völkel, C., Hinsch, A., Gorbokon, N., Lennartz, M., Hube-Magg, C., Fraune, C., Bernreuther, C., Lebok, P., Clauditz, T. S., Jacobsen, F., Sauter, G., Uhlig, R., Wilczak, W., Steurer, S., Minner, S., ... Luebke, A. M. (2022). Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. PATHOBIOLOGY, 89(4), 245-258. https://doi.org/10.1159/000522206

Vancouver

Dum D, Taherpour N, Menz A, Höflmayer D, Völkel C, Hinsch A et al. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. PATHOBIOLOGY. 2022;89(4):245-258. https://doi.org/10.1159/000522206

Bibtex

@article{2e4dcb60d4e541eebd745b312802cfb0,
title = "Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors",
abstract = "INTRODUCTION: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.METHODS: A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.RESULTS: TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.CONCLUSION: TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.",
author = "David Dum and Noushin Taherpour and Anne Menz and Doris H{\"o}flmayer and Cosima V{\"o}lkel and Andrea Hinsch and Natalia Gorbokon and Maximilian Lennartz and Claudia Hube-Magg and Christoph Fraune and Christian Bernreuther and Patrick Lebok and Clauditz, {Till S} and Frank Jacobsen and Guido Sauter and Ria Uhlig and Waldemar Wilczak and Stefan Steurer and Sarah Minner and Marx, {Andreas H} and Ronald Simon and Eike Burandt and Till Krech and Luebke, {Andreas M}",
note = "{\textcopyright} 2022 S. Karger AG, Basel.",
year = "2022",
doi = "10.1159/000522206",
language = "English",
volume = "89",
pages = "245--258",
journal = "PATHOBIOLOGY",
issn = "1015-2008",
publisher = "S. Karger AG",
number = "4",

}

RIS

TY - JOUR

T1 - Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors

AU - Dum, David

AU - Taherpour, Noushin

AU - Menz, Anne

AU - Höflmayer, Doris

AU - Völkel, Cosima

AU - Hinsch, Andrea

AU - Gorbokon, Natalia

AU - Lennartz, Maximilian

AU - Hube-Magg, Claudia

AU - Fraune, Christoph

AU - Bernreuther, Christian

AU - Lebok, Patrick

AU - Clauditz, Till S

AU - Jacobsen, Frank

AU - Sauter, Guido

AU - Uhlig, Ria

AU - Wilczak, Waldemar

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Marx, Andreas H

AU - Simon, Ronald

AU - Burandt, Eike

AU - Krech, Till

AU - Luebke, Andreas M

N1 - © 2022 S. Karger AG, Basel.

PY - 2022

Y1 - 2022

N2 - INTRODUCTION: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.METHODS: A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.RESULTS: TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.CONCLUSION: TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.

AB - INTRODUCTION: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.METHODS: A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.RESULTS: TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.CONCLUSION: TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.

U2 - 10.1159/000522206

DO - 10.1159/000522206

M3 - SCORING: Journal article

C2 - 35477165

VL - 89

SP - 245

EP - 258

JO - PATHOBIOLOGY

JF - PATHOBIOLOGY

SN - 1015-2008

IS - 4

ER -